US20060178305A1 - Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof - Google Patents

Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof Download PDF

Info

Publication number
US20060178305A1
US20060178305A1 US11/293,761 US29376105A US2006178305A1 US 20060178305 A1 US20060178305 A1 US 20060178305A1 US 29376105 A US29376105 A US 29376105A US 2006178305 A1 US2006178305 A1 US 2006178305A1
Authority
US
United States
Prior art keywords
vegf
trap
inhibitor
folinic acid
vegf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/293,761
Other languages
English (en)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Jesse Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Regeneron Pharmaceuticals Inc
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060178305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of US20060178305A1 publication Critical patent/US20060178305A1/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CEDARBAUM, JESSE M., HOLASH, JOCELYN, FURFINE, ERIC
Assigned to AVENTIS PHARMA S.A.. reassignment AVENTIS PHARMA S.A.. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BISSERY-CHABOT, MARIE-CHRISTINE, CHIRON-BLONDEL, MARIELLE, VRIGNAUD, PATRICIA
Priority to US12/508,834 priority Critical patent/US8388963B2/en
Priority to US13/783,919 priority patent/US20130184205A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to combinations of a VEGF inhibitor and a chemotoxic agent of the class of 5-fluorouracil or 5-fluoropyrimidines that are useful in the treatment of neoplastic diseases.
  • VEGF inhibitors which are inhibitors of vascular endothelial growth factor, are, in the majority of cases, biological products chosen from soluble receptors, antisenses, RNA aptamers and antibodies.
  • the 5-fluoropyrimidine derivatives are chosen from 5-fluorouracil, capecitabine or gemcitabine, which exhibit notable antitumoral and antileukemia properties; they are particularly useful in the treatment of ovarian cancer, breast cancer, lung cancer or colon cancer.
  • the present combination is directed in particular toward the treatment of colon cancer or stomach cancer.
  • the VEGF-Trap used in the invention is a fusion protein comprising the VEGFR1 signal sequence fused to the Ig domain D2 of the VEGFR1 receptor, itself fused to the Ig domain D3 of the VEGFR2 receptor, in turn fused to the Fc domain of IgG1, also called VEGFR1R2-Fc ⁇ C1 or Flt1D2.FlklD3.Fc ⁇ C 1.
  • the doses used are between 20 and 800 micrograms per kilo when the administration is carried out subcutaneously and from 2 to 20 micrograms per kilo when the administration is carried out intravenously or, optionally, intranasally at a lower dose of the order of 0.01 picogram to 1 mg per kilo.
  • the 5-fluorouracil is generally used intravenously at a dose of between 500 mg/m 2 and 5000 mg/m 2 per week; as regards the 5-fluoropyrimidine derivatives such as capecitabine, they are generally used, for the latter, orally at a dose of between 500 and 3000 mg/m 2 generally administered in two daily doses.
  • Gemcitabine is generally used intravenously at a dose of between 500 and 2000 mg/m 2 per week.
  • VEGF inhibitors can be considerably improved when they are administered in combination with at least one substance therapeutically useful in anticancer treatments that has a mechanism of action different from that of the VEGF inhibitors.
  • the activity of the products depends on the doses used, it is possible to use higher doses and to increase the activity by decreasing the phenomena of toxicity or delaying their appearance through the combination with the VEGF inhibitors or with their analogs of other therapeutically active substances, of growth factors of hematopoietic type, such as G-CSF or GM-CSF, or certain interleukins.
  • the invention relates to the combinations of VEGF-Trap with 5-fluorouracil or derivatives thereof such as capecitabine or gemcitabine. It also relates to the combinations also including folinic acid generally combined with 5-FU.
  • a combination shows therapeutic synergism if it is therapeutically superior to one or other of the constituents used at its optimum dose [T. H. Corbett et al., Cancer Treatment Reports, 66, 1187 (1982)].
  • T-C represents the delay in growth of the cells, which is the average time, in days, for the tumors of the treated group (T) and the tumors of the control group (C) to reach a predetermined value (1 g, for example) and T d represents the time, in days, required for the volume of the tumor to double in the control animals [T. H.
  • a product is considered to be active if log 10 killed cells is greater than or equal to 0.7.
  • a product is considered to be very active if the log 10 killed cells is greater than 2.8.
  • each of the constituents will be present at a dose generally less than or equal to its maximum tolerated dose, which show therapeutic synergy when the log 10 killed cells is greater than the value of log 10 killed cells of the best constituent when it is administered alone.
  • an MC 13/C mammary tumor fragment are transplanted bilaterally, subcutaneously, into the animals subjected to the experiment, generally mice, on day 0.
  • the animals bearing the tumors are randomized before being subjected to the various treatments and controls. In the case of treatment of advanced tumors, the tumors are left to develop until the desired size, the animals having insufficiently developed tumors being eliminated.
  • the animals selected are divided up randomly so as to undergo the treatments and the controls. Animals not bearing tumors can also be subjected to the same treatments as the tumor-bearing animals in order to be able to dissociate the toxic effect from the actual effect on the tumor.
  • the chemotherapy generally begins from 3 to 22 days after the tumor transplant, according to the type of tumor, and the animals are observed every day.
  • the various groups of animals are weighed three or four times a week until the maximum weight loss is obtained, and then the groups are weighed at least once a week until the end of the trial.
  • the tumors are measured two or three times a week until the tumor reaches approximately 2 g or until the animal's death if the latter occurs before the tumor reaches 2 g.
  • the animals are autopsied when they are sacrificed.
  • the antitumor activity is determined as a function of the various parameters recorded.
  • a product is considered to be active if the increased survival time is greater than 27% and it is considered to be very active if it is greater than 75% in the case of P388 leukemia.
  • the present invention also relates to the pharmaceutical compositions containing the combinations according to the invention.
  • the products that constitute the combination can be administered simultaneously, separately or spread out over time so as to obtain the maximum effectiveness of the combination; it being possible for each administration to have a variable duration ranging from complete rapid administration to continuous infusion.
  • the combinations are not only limited to those which are obtained by physical combination of the constituents, but also to those which allow a separate administration which may be simultaneous or spread out over time.
  • compositions according to the invention are preferably compositions that can be administered parenterally. However, these compositions may be administered orally.
  • compositions for parenteral administration are generally sterile pharmaceutically acceptable solutions or suspensions which may optionally be prepared extemporaneously at the time of use.
  • nonaqueous solutions or suspensions natural plant oils such as olive oil, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate can be used.
  • the aqueous sterile solutions may consist of a solution of the product in water.
  • the aqueous solutions are suitable for intravenous administration insofar as the pH is suitably adjusted and isotonicity is effected, for example by means of a sufficient amount of sodium chloride or glucose.
  • the sterilization can be carried out by heating or by any other means that does not impair the composition.
  • the combinations may also be in the form of liposomes or in the form of a combination with carriers such as cyclodextrins or polyethylene glycols.
  • the application of these constituents may be simultaneous, separate or spread out over time, it is particularly advantageous for the amount of VEGF-Trap derivative to represent from 2 to 80% by weight of the combination, it being possible for this content to vary according to the nature of the substance combined, to the desired effectiveness and to the nature of the cancer to be treated.
  • “Pharmaceutically effective amount” is meant to describe an amount of the combinations according to the present invention, and constituents thereof, effective in producing the desired therapeutic effect.
  • the constituents of the combinations according to the invention may be administered in dosages which are pharmaceutically effective for each constituent, or in dosages which are sub-clinical, i.e., less than pharmaceutically effective for each, or a combination thereof, provided that the combined dosages are pharmaceutically effective.
  • the combinations according to the invention are particularly useful in the treatment of colon and/or stomach cancers.
  • they may have the advantage of being able to use the constituents at doses that are much lower than those at which they are used alone.
  • Ampoules of 1 cm 3 containing 25 mg of VEGF-Trap, which are diluted in a phosphate buffer, are prepared, according to the usual technique, for subcutaneous administration.
  • 0.2 ml per mouse is prepared, according to the usual technique, for intravenous administration, from a commercial solution of 5 cm 3 containing 250 mg of 5 FU to be diluted with 5% glucose in water.
  • the treatment can be repeated several times per day or per week until partial or complete remission or recovery.
  • Dosage in mg/kg/day total dose in mg/kg) % sc VEGF- weight Trap loss at (day 4, 7, iv 5-FU Death due the 11, 14, 18, (day 4, 11, to the lowest T ⁇ C 21) 18) treatment point % T/C days lck 40 (240) — 0/5 2.3 4 12.7 1.4 25 (150) — 0/5 1.1 8 13.9 1.5 10 (60) — 0/5 1.1 9 12.1 1.3 2.5 (15) — 0/5 0.9 32 5.2 0.6 — 145 (435) 1/5 8.7 Toxic — — — 90 (270) 0/5 4.8 0 12.5 1.3 — 55.8 (167.4) 0/5 1.1 12 7.8 0.8 — 34.6 (103.8) 0/5 +2.3 34 4.6 0.5 40 (240) 90 (270) 0/5 8.0 0 25.2 2.7 25 (150) 90 (270

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/293,761 2004-12-03 2005-12-02 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof Abandoned US20060178305A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/508,834 US8388963B2 (en) 2004-12-03 2009-07-24 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US13/783,919 US20130184205A1 (en) 2004-12-03 2013-03-04 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
FR0412870 2004-12-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/508,834 Continuation US8388963B2 (en) 2004-12-03 2009-07-24 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

Publications (1)

Publication Number Publication Date
US20060178305A1 true US20060178305A1 (en) 2006-08-10

Family

ID=34954452

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/293,761 Abandoned US20060178305A1 (en) 2004-12-03 2005-12-02 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US12/508,834 Active US8388963B2 (en) 2004-12-03 2009-07-24 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US13/783,919 Abandoned US20130184205A1 (en) 2004-12-03 2013-03-04 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/508,834 Active US8388963B2 (en) 2004-12-03 2009-07-24 Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US13/783,919 Abandoned US20130184205A1 (en) 2004-12-03 2013-03-04 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof

Country Status (26)

Country Link
US (3) US20060178305A1 (ja)
EP (1) EP1824504B1 (ja)
JP (1) JP4980236B2 (ja)
KR (1) KR101313404B1 (ja)
CN (1) CN101068564B (ja)
AT (1) ATE426409T1 (ja)
AU (1) AU2005311191C1 (ja)
BR (1) BRPI0518700B8 (ja)
CA (1) CA2586735C (ja)
CY (3) CY1109181T1 (ja)
DE (1) DE602005013568D1 (ja)
DK (1) DK1824504T3 (ja)
ES (1) ES2324233T3 (ja)
FR (1) FR2878749B1 (ja)
HK (1) HK1114769A1 (ja)
HR (1) HRP20090336T1 (ja)
IL (1) IL183481A (ja)
LU (2) LU92203I2 (ja)
ME (1) ME01706B (ja)
MX (1) MX2007006607A (ja)
PL (1) PL1824504T3 (ja)
PT (1) PT1824504E (ja)
RS (1) RS50769B (ja)
RU (1) RU2384344C2 (ja)
SI (1) SI1824504T1 (ja)
WO (1) WO2006059012A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160233A1 (en) * 2007-07-05 2010-06-24 Aventis Pharma S.A. Antitumour combinations containing a vegf inhibiting agent and irinotecan
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014667A1 (en) * 1999-06-08 2004-01-22 Daly Thomas J. VEGF traps and therapeutic uses thereof
US20050032699A1 (en) * 2003-07-25 2005-02-10 Jocelyn Holash Composition of a VEGF antagonist and an anti-proliferative agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014667A1 (en) * 1999-06-08 2004-01-22 Daly Thomas J. VEGF traps and therapeutic uses thereof
US20050032699A1 (en) * 2003-07-25 2005-02-10 Jocelyn Holash Composition of a VEGF antagonist and an anti-proliferative agent
US7354579B2 (en) * 2003-07-25 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160233A1 (en) * 2007-07-05 2010-06-24 Aventis Pharma S.A. Antitumour combinations containing a vegf inhibiting agent and irinotecan
US20140127202A1 (en) * 2007-07-05 2014-05-08 Aventis Pharma S.A. Antitumour combinations containing a vegf inhibiting agent and irinotecan
CN105833244A (zh) * 2007-07-05 2016-08-10 艾文蒂斯药品公司 含有vegf抑制剂和伊立替康的抗肿瘤组合
US20190275147A1 (en) * 2007-07-05 2019-09-12 Aventis Pharma S.A. Antitumour combinations containing a vegf inhibiting agent and irinotecan
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Also Published As

Publication number Publication date
ES2324233T3 (es) 2009-08-03
CA2586735C (fr) 2014-08-12
SI1824504T1 (sl) 2009-08-31
JP4980236B2 (ja) 2012-07-18
CN101068564A (zh) 2007-11-07
IL183481A0 (en) 2007-09-20
FR2878749A1 (fr) 2006-06-09
RU2384344C2 (ru) 2010-03-20
LU92203I2 (fr) 2013-11-15
LU92202I9 (ja) 2019-01-15
CY2013017I1 (el) 2014-07-02
BRPI0518700B8 (pt) 2021-05-25
RU2007123607A (ru) 2009-01-10
DE602005013568D1 (de) 2009-05-07
KR20070091130A (ko) 2007-09-07
ATE426409T1 (de) 2009-04-15
AU2005311191A1 (en) 2006-06-08
AU2005311191B2 (en) 2011-12-08
WO2006059012A1 (fr) 2006-06-08
AU2005311191C1 (en) 2015-04-30
CA2586735A1 (fr) 2006-06-08
PT1824504E (pt) 2009-06-25
BRPI0518700B1 (pt) 2020-02-11
LU92203I9 (ja) 2019-01-15
HRP20090336T1 (en) 2009-07-31
BRPI0518700A2 (pt) 2008-12-02
DK1824504T3 (da) 2009-07-20
CN101068564B (zh) 2010-12-15
RS50769B (sr) 2010-08-31
CY2013018I1 (el) 2020-05-29
LU92202I2 (fr) 2013-11-15
PL1824504T3 (pl) 2009-08-31
HK1114769A1 (en) 2008-11-14
KR101313404B1 (ko) 2013-10-01
CY1109181T1 (el) 2014-07-02
FR2878749B1 (fr) 2007-12-21
JP2008521866A (ja) 2008-06-26
US8388963B2 (en) 2013-03-05
EP1824504A1 (fr) 2007-08-29
MX2007006607A (es) 2007-07-25
EP1824504B1 (fr) 2009-03-25
ME01706B (me) 2010-08-31
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
IL183481A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
US8388963B2 (en) Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
US20190275147A1 (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
KR100334051B1 (ko) 탁산유도체를함유하는항종양조성물
KR101226631B1 (ko) 항암 치료 방법
CN107206053A (zh) 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法
KR20210039414A (ko) 암의 치료를 위한 병용 요법
TW202435896A (zh) 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物
Mishima et al. Sequential treatment with irinotecan and doxifluridine: Optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer
US20090196869A1 (en) Antitumor combinations containing taxane derivatives
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FURFINE, ERIC;HOLASH, JOCELYN;CEDARBAUM, JESSE M.;REEL/FRAME:020842/0112;SIGNING DATES FROM 20080320 TO 20080328

AS Assignment

Owner name: AVENTIS PHARMA S.A.., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VRIGNAUD, PATRICIA;CHIRON-BLONDEL, MARIELLE;BISSERY-CHABOT, MARIE-CHRISTINE;REEL/FRAME:021239/0098

Effective date: 20080602

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION